Price T Rowe Associates Inc Vaxcyte, Inc. Transaction History

Price T Rowe Associates Inc

$883 Billion
Q2 2025

A detailed history of Price T Rowe Associates Inc transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 3,170,247 shares of PCVX stock, worth $103 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,170,247

Previous 3,542,007 10.5%

Holding current value

$103 Million

Previous $134 Million 22.94%

% of portfolio

0.01%

Previous 0.02%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$28.04 - $37.2 $10.4 Million - $13.8 Million	-371,760 Reduced 10.5%	3,170,247 $103 Million
Q1 2025 May 14, 2025	SELL	$37.76 - $92.13 $16 Million - $39.2 Million	-424,949 Reduced 10.71%	3,542,007 $134 Million
Q4 2024 Feb 14, 2025	SELL	$80.97 - $117.93 $40.4 Million - $58.9 Million	-499,181 Reduced 11.18%	3,966,956 $325 Million
Q3 2024 Nov 14, 2024	BUY	$70.52 - $117.12 $91.2 Million - $151 Million	1,292,970 Added 40.75%	4,466,137 $510 Million
Q2 2024 Aug 14, 2024	SELL	$60.06 - $78.77 $181,020 - $237,412	-3,014 Reduced 0.09%	3,173,167 $240 Million
Q1 2024 May 15, 2024	BUY	$59.79 - $81.05 $29.8 Million - $40.4 Million	498,359 Added 18.61%	3,176,181 $217 Million
Q4 2023 Feb 14, 2024	BUY	$45.35 - $63.41 $11.8 Million - $16.5 Million	260,170 Added 10.76%	2,677,822 $168 Million
Q3 2023 Nov 14, 2023	BUY	$46.0 - $53.1 $10.4 Million - $12 Million	225,270 Added 10.28%	2,417,652 $123 Million
Q2 2023 Aug 14, 2023	BUY	$34.66 - $54.07 $74.9 Million - $117 Million	2,160,354 Added 6745.2%	2,192,382 $109 Million
Q1 2023 May 15, 2023	BUY	$36.27 - $47.2 $63,835 - $83,072	1,760 Added 5.81%	32,028 $1.2 Million
Q4 2022 Feb 14, 2023	BUY	$20.58 - $47.95 $446,935 - $1.04 Million	21,717 Added 253.97%	30,268 $1.45 Million
Q3 2022 Nov 14, 2022	SELL	$21.69 - $28.53 $116,627 - $153,405	-5,377 Reduced 38.61%	8,551 $206,000
Q2 2022 Aug 15, 2022	BUY	$17.68 - $26.58 $21,569 - $32,427	1,220 Added 9.6%	13,928 $303,000
Q1 2022 May 16, 2022	BUY	$17.46 - $26.36 $19,677 - $29,707	1,127 Added 9.73%	12,708 $307,000
Q4 2021 Feb 14, 2022	SELL	$19.32 - $26.45 $15,456 - $21,160	-800 Reduced 6.46%	11,581 $276,000
Q3 2021 Nov 15, 2021	BUY	$20.26 - $26.97 $41,370 - $55,072	2,042 Added 19.75%	12,381 $314,000
Q2 2021 Aug 16, 2021	BUY	$16.45 - $24.06 $170,076 - $248,756	10,339 New	10,339 $233,000

Others Institutions Holding PCVX

# of Institutions

324

Shares Held

139M

Call Options Held

229K

Put Options Held

160K

View Full List

About Vaxcyte, Inc.

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $1.92B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

More about PCVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Vaxcyte, Inc. Transaction History